The US has the ability to increase R&D and make a global impact through coordination with other countries. The Access to COVID Tools (ACT) proves.
Lurie, et al 21
[Nicole Lurie received her BA and MD from the University of Pennsylvania and served an 8-year term as Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. Gerald T. Keusch received his BA from Columbia College and his MD from Harvard Medical School. He is a professor and Associate Director of Medicine and International Health at Boston University. Victor J. Dzau received his BA and MD from McGill University and currently serves as the President of the United States National Academy of Medicine of the United States National Academy of Sciences. He was previously the president and CEO of Duke University Medical Center. “Urgent lessons from COVID-19: why the world needs a standing, coordinated system and sustainable financing for global research and development,” https://doi.org/10.1016/ S0140-6736(21)00503-1.] cgarland
The USA, a large, wealthy, sovereign nation, has important advantages when it comes to its R&D preparedness and response ecosystem. Through its government agencies, including NIH, the US Centers for Disease Control and Prevention, Biomedical Advanced Research and Development Authority, US Food and Drug Administration, and Department of Defense, the USA has the resources, funding, and coordination necessary to sustain essential end-to-end R&D functions before and during a pandemic. The US Government supports basic and translational research, public and private sector development partner- ships, and early and sustained development of products, including clinical trials, manufacture, regulatory approval, procurement and, ultimately, distribution of products. It also has a strong private sector pharmaceutical and biotechnology sector able, if not necessarily always willing, to engage in pandemic disease research, manufacture, and distribution of new products. During the COVID-19 pandemic, many of these organisational roles have been taken on by ACTIV and Operation Warp Speed—emergency programmes to identify useful therapeutics and to fund at-risk vaccine development, production, and advanced purchase contracts.20,22 On Jan 15, 2021 the incoming Biden administration announced that Operation Warp Speed would be phased out and a new structure would be created within the White House Coronavirus office to focus on improving vaccine distribution under new leadership.23 Although there were many shortcomings in the US response to the pandemic, vaccine R&D was not among them—witness the collaboration between NIAID and Moderna Therapeutics to develop its mRNA vaccine candidate and Operation Warp Speed to move vaccine production forward by funding development and manufacturing before proof of efficacy was available.15,22 However, the primary intent of this effort was to produce products explicitly for USA use; substantial public funding covered much or all of the cost of development and advanced purchase for some products, with a goal that they would be free to the USA public during the pandemic. Advance purchase commitments might not be sufficient, however, for companies to sell their products at a price affordable globally, especially to low-income countries. In contrast, the global system, comprised of 195 member nations of the UN and its agencies, is fragmented, poorly coordinated, and under-resourced. Some of these countries (for example the UK, France, Germany, Russia, China, India, and a few others) have remarkable scientific expertise and financial and infrastructure resources, but only a few can support an end-to-end R&D system from basic research before a crisis to approved products during the response to an outbreak. Some countries, such as the USA or Russia, followed their own path without collaborating with any coordinated global effort. Although the R&D roles and responsibilities for the various components of the ecosystem might be apparent, it is at best uncertain which entities have the responsibility and resources to support a global system for the multitude of essential activities for development and deployment. Although recognising that the global system is comprised of the efforts of individual countries, as well as scientists and multinational companies and organisations, the table identifies the major R&D activities required for the emerging end-to-end R&D preparedness and response ecosystem, contrasts US and global capacity, highlights the gaps revealed during the COVID-19 pandemic in the USA and around the world, and indicates what needs to be created, developed, and financed. CEPI had already recognised some of these needs for vaccine development, even before January, 2020;24 however, there were no global entities with a clear mandate, responsibility, or resources to initiate product development in a pandemic. There were also no recognised organisations to support a pathogen repository, host their sequence information, grow and share virus isolates for essential research, and organise and collect biological reference materials from patients to support product development and validation of new diagnostic tests. Fortunately, some organisations simply stood up and did the right thing using their existing resources, but the ability to support, let alone to coordinate, investigators around the world was inadequate. In early January, 2020, as the first reports of the new outbreak in China became evident, CEPI mobilised the vaccine developers that it was already supporting to discuss how to pivot ongoing R&D to COVID-19. CEPI executed its first COVID-19 vaccine development agreements later that month.24 In contrast, the lack of similar pre-existing go-to entities to activate development of diagnostics and therapeutics, or other essential products, soon became apparent. Had there been a CEPI-like entity for diagnostics or therapeutics could these essential products have been created more rapidly? What seems likely is that shortening deployment of diagnostics and therapeutics by a few weeks would have favourably and substantially altered the evolution of the pandemic and saved many lives. Unlike the USA and a few other countries, the rest of the world faced a resource and responsibility challenge because there were no global entities with a mandate, financing arrangements, or the ability to coordinate multiple independent actors to test, approve, manufac- ture, scale up, or ensure equitable global access to new products. Instead, advanced purchase commitments negotiated by high-income countries with major pharmaceutical and biotech companies for vaccines and diagnostics threatened to consume all the early supply. High-income countries, which account for 14% of the world’s population, made deals during 2020 with manufacturers for over 50% of the anticipated supply of vaccines.25 This competitive dynamic among wealthy nations, characterised as vaccine nationalism, served to drive up prices for everyone and leave out half of the world’s population living in low-income and middle- income countries from timely access to the same products.26 In response to the urgent need for global coordinated action, an unprecedented gathering of heads of govern- ments, institutions, and industries took place in late April, 2020, to commit to work together to accelerate development, production, procurement, and delivery of COVID-19 health technologies that can control and end the pandemic. The Access to COVID Tools (ACT) Accelerator was formed as a 2-year, term limited, coalition of global heath organisations including the Bill and Melinda Gates Foundation, CEPI, Gavi (the Vaccine Alliance), the Global Fund, UNITAID, Wellcome Trust, and WHO; private sector partners; and other stakeholders to collaborate to accelerate the development and ensure the equitable distribution of COVID diagnostics, treat- ments, and vaccines.27 The ACT Accelerator has made substantial strides towards these goals in its first 9 months, providing access to rapid diagnostic tests and treatments (eg, dexamethasone and oxygen), and by establishing the COVID-19 Vaccine Facility (COVAX), which is pooling global resources to expedite the development, manu- facture, and procurement of vaccines to ensure global equitable access.28 Although the ACT Accelerator and COVAX are promising initiatives, with 43 current donor governments, foundations, corporations and organisations listed on the Gavi COVAX hub29 at the time of publication, a few countries with financial ability to support this effort initially refused to join, and current funding pledges remain grossly inadequate for the need. The gaps in manufacturing, procurement, and equitable access to diagnostics, therapeutics, and other essential products are even more striking than those related to vaccines, and mechanisms to address them have been slower to develop. In all these areas, inadequate financial support and major dependence on the private sector has been a substantial impediment for products developed through the R&D ecosystem to reach all who are in need. Financing of ACT Accelerator has depended primarily on donor funds designated for assistance to low-income countries; this is an inadequate model, either to meet global needs in a pandemic or to finance the type of global R&D infrastructure that is required for the future, particularly as pandemics impact the entire world. Furthermore, global financing instruments to support the ramp up of manufacturing at scale and, if necessary, at risk, and funding to procure products must be in place at the front end of the response to a pandemic. Fundraising during a pandemic cannot get the job done; in fact, it diverts attention from essential R&D and programme implementation and further delays equitable access.